



First Description of an Enteric-Type Adenocarcinoma with a High-Grade Neuroendocrine Component of the Lung

Irene Moya-Horno¹, Rodolfo Posada², Clara Mayo³, Miguel Ángel Molina³, María Teresa Fernández-Figueras^{2,4}, Manel Esteller^{5,6,7,8} and Eva Musulén^{2,5*}

¹Department of Medical Oncology, Instituto Oncológico Dr Rosell, Hospital Universitari General de Catalunya Grupo Quironsalud, Barcelona, Spain

²Department of Pathology, Hospital Universitari General de Catalunya-Grupo Quironsalud, Sant Cugat del Vallès, Barcelona, Spain

³Laboratory of Oncology, Pangaea Oncology, Hospital Universitari Quirón Dexeus, Barcelona, Spain

⁴Universitat Internacional de Catalunya (UIC), Sant Cugat del Vallès, Barcelona, Spain

⁵Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain

⁶Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain

⁷Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Spain

⁸Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain

Abstract

Background: Pulmonary Enteric-type Adenocarcinoma (PEAC) is a rare variant of Non-Small Cell Lung Cancer (NSCLC) characterized by similar morphology and immunohistochemical expression to primary colon adenocarcinoma.

Case Report: A 58-year-old smoker female was submitted to a complete lobectomy due to a mass without lymph node involvement. The resected tumor was a PEAC with a biphasic histologic morphology with one component of glands with a cribriform and acinar pattern with luminal necrosis, and the other component with cells with eosinophilic or clear cytoplasm and round nuclei with prominent nucleoli appearing in a solid growth pattern. The gland cells expressed markers of lung and enteric differentiation such as TTF-1, Cytokeratin 20 (CK20), and CDX2, while the solid component cells showed expression of CK20 and synaptophysin with a Ki-67 proliferation index of 65% defining them as a high-grade Neuroendocrine Carcinoma (NEC). The neoplasm metastasized first to the left clavicle and rapidly spread to multiple bones, cerebellum and pancreas at the expense of the NEC component resulting in the patient's death twelve months after diagnosis of the lung neoplasm. Both PEAC and clavicle tumor shared *KRAS* p.G12V and *TP53* c.375+1G>C mutations but *CDK6* amplification, a frequent genetic alteration of neuroendocrine differentiation, was only found at the metastasis.

Conclusion: We describe in this study the first case of Pulmonary Enteric-type Mixed Adenoneuroendocrine Carcinoma (PEMANEC) in analogy to colon neoplasms, where an adenocarcinoma with a high-grade neuroendocrine component is defined as a Mixed Adenoneuroendocrine Carcinoma (MANEC).

Keywords: Pulmonary enteric-type adenocarcinoma; Neuroendocrine carcinoma; Pulmonary enteric-type mixed adenoneuroendocrine carcinoma

Introduction

Pulmonary Enteric-type Adenocarcinoma (PEAC) is a rare variant of Non-Small Cell Lung Cancer (NSCLC) with almost 300 cases described [1,2]. First described in 1991 by Tsao and Fraser [3], PEAC is defined as an adenocarcinoma that resembles the adenocarcinoma arising in the colorectum in $\geq 50\%$ of tumor, with expression of at least one intestinal marker such as Caudal-type homeobox 2 (CDX2) and/or Cytokeratin 20 (CK20), HNF4 α , or MUC2, and clinical exclusion of metastatic CRC (mCRC) [4].

We report a PEAC with a component of high-grade Neuroendocrine Carcinoma (NEC) that rapidly spread to multiple locations conferring to the tumor a very aggressive and lethal course.

OPEN ACCESS

*Correspondence:

Eva Musulén, Department of Pathology, Hospital Universitari General de Catalunya-Grupo Quironsalud, Sant Cugat del Vallès, Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Spain, E-mail: eva.musulen@quironsalud.es

Received Date: 05 Oct 2021

Accepted Date: 29 Oct 2021

Published Date: 05 Nov 2021

Citation:

Moya-Horno I, Posada R, Mayo C, Molina MÁ, Fernández-Figueras MT, Esteller M, et al. First Description of an Enteric-Type Adenocarcinoma with a High-Grade Neuroendocrine Component of the Lung. *Clin Oncol*. 2021; 6: 1876.

ISSN: 2474-1663

Copyright © 2021 Eva Musulén. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.




Figure 1: CT image, microscopic appearance and immunohistochemical profile of the lung neoplasm. A) Peripheral lung mass in the right upper lobe on chest CT before transthoracic biopsy. B) The tumor was mostly composed of glands with extensive necrosis but in some areas there was solid growth (arrowhead). C) The glands showed a cribriform pattern with dirty necrosis in the lumen. D) In the poorly differentiated areas the cells showed an eosinophilic cytoplasm and a round nucleus with prominent nucleolus. E) In some sections the two components were merged. F) TTF-1 was expressed in neoplastic glands and in some residual lung parenchymal cells that served as a positive internal control (arrow). G) CK20 was only expressed in glandular cells. H) CDX2 was diffusely expressed in the glandular component and only a few positive nuclei were present among the cells of the solid clusters. I) Synaptophysin was only positive in the high-grade neuroendocrine component.

In CRC a mixed adenocarcinoma that shows a NEC component is designed as Mixed Adenoneuroendocrine Carcinoma (MANEC) now under the umbrella category of MiNENs (Mixed Neuroendocrine-non-Neuroendocrine Neoplasms) in the last WHO classification of digestive system tumors [5]. Compared with CRC, MANEC is an aggressive neoplasm with poorer outcomes. Median overall survival of colorectal MANEC is around one year and depends on stage and Ki-67 proliferation index.

Although in other lung cancers such as in high-grade fetal adenocarcinoma, a combination with NEC has been reported in around 20% of cases [6-8], to the best of our knowledge, this is the first time that a NEC component is described in a PEAC.

Therapeutic strategies for PEAC essentially derive from recommendations for the treatment of lung adenocarcinoma as NSCLC and specific guidance is lacking. Oncogenic driver mutations in PEAC have been reported in case reports and small case series, being the *KRAS* mutation the most frequently detected in these tumors [9-18]. Wide use of Next Generation Sequencing (NGS) may reveal molecular signatures of PEAC to guide treatment options [15,17,19].

Herein we report a PEAC with a NEC component as the first primary PEMANEC of the lung.

Case Presentation

A 58-year-old smoker female with family history of colorectal

adenomas was referred to hospital with shortness of breath and cough for over two months. Past medical history was remarkable for dyslipidemia and endoscopic removal of a left CRC with sub mucosal invasion (pT1) with low-grade histology, no lymphovascular invasion and negative margins five years ago. Chest X-ray and contrast-enhanced Computed Tomography (CT) showed a peripheral lung mass in the right upper lobe without mediastinal lymph node involvement. On Positron Emission Tomography (PET)-CT, the mass presented as a unique lobulated lesion measuring 46 mm × 59 mm and high 18F-FDG uptake. A percutaneous transthoracic CT-guided core biopsy of the mass resulted non-conclusive due to necrosis (Figure 1). The patient underwent thoracic surgery and a complete lobectomy with mediastinal lymph node dissection was performed.

Lobectomy showed a 10 cm tumor with pleural retraction. On section, the tumor was poorly demarcated and with extensive necrosis. Microscopically, the neoplasm presented a biphasic histologic morphology with a component of glands in a cribriform pattern with dirty luminal necrosis and other poorly differentiated component having cells with eosinophilic or clear cytoplasm and round nuclei with prominent nucleoli appearing in a solid growth pattern (Figure 1). In some sections these solid nests merged with the glands. No lymphovascular or perineural invasion was identified and the visceral pleura was not infiltrated. Neoplastic gland cells showed expression for TTF-1, CK20, CDX2, and SATB2 while CK7 was negative (Figure 1 and Table 1).

Table 1: Immunohistochemical markers used for the diagnosis of the resected lung primary tumor and both the clavicle and the pancreatic metastases.

Marker	Lung		Clavicle	Pancreas
	Epithelial component	NE component		
CK7	-	-	-	-
CK20	+	-	-	-
TTF-1	+	-	-	-
Napsin A	-	-	-	-
CDX2	+	+	+	+
SATB2	+	-	-	-
Synaptophysin	-	+	+	+

Abbreviations: NE: Neuroendocrine; +: Positive; -: Negative

The diagnosis was PEAC with no mediastinal lymph node involvement, stage pT4N0 and free margins. PD-L1 expression resulted negative <1% and no microsatellite instability was observed. Analysis by NGS detected *KRAS* p.G12V (43%) and *TP53* c.375+1G>C (65%) mutations.

After a postoperative surveillance period free of complications, the patient was referred to a digestive endoscopy unit to exclude lung metastases of colorectal origin. A complete rectocolonoscopy identified a tattoo in the left colon marking previous endoscopically resected pT1 colon adenocarcinoma, with no tumor recurrence at this site on histological examination.

Patient initiated follow-up visits with a chest CT showing postoperative changes and no evidence of thoracic recurrence.

Three months later the patient consulted for a progressive swelling in the left shoulder causing pain and functional impairment. A hard fixed mass was palpable on physical exam and a Magnetic Resonance Imaging (MRI) identified soft tissue infiltration overlying a 40 mm × 37 mm in size lytic lesion of the left distal clavicle (Figure 2).

Performed core biopsy demonstrated infiltration by poorly differentiated carcinoma staining negative for TTF-1, CK20, CK7, and napsin A, and positive for CDX2 and synaptophysin (Figure 2). At that time, synaptophysin immunostaining was performed on the poorly differentiated component of PEAC, resulting positive with a

Table 2: NGS findings within the resected lung primary tumor and metastases.

Gene	Lung	Clavicle	Pancreas
<i>KRAS</i> G12V	+	+	NP
<i>TP53</i> c.375+1G>C	+	+	NP
<i>CDK6</i> amplification	-	+	NP

Abbreviations: +: Positive; -: Negative; NP: Not Performed


Ki-67 proliferative index expression of 65%, confirming the presence of a NEC component (Figure 1 and Table 1). NGS was performed on the clavicle tumor detecting the same mutations as in PEAC, with acquisition of *CDK6* amplification (Table 2).

At this point, workup with body CT, bone scintigraphy, PET-CT and brain MRI revealed coexisting metastasis in the left cerebellum and in many other bone structures. A pancreatic mass with locoregional lymph node spread was also detected (Figure 2). There was no evidence of disease recurrence in lung and blood levels of tumor markers CEA and CA19-9 were not raised. Pancreatic tissue biopsy obtained by endoscopic ultrasound-guided fine needle aspiration confirmed malignant infiltration by poorly differentiated carcinoma, with an immunohistochemical profile comparable to the clavicle metastasis (Figure 2), supporting the diagnosis of bone and pancreatic metastatic PEAC at the expense of NEC component (Table 1).

The patient underwent brain stereotactic radiosurgery and left shoulder radiotherapy for antalgic purpose. Platinum-based chemotherapy with pemetrexed in combination with pembrolizumab was also initiated. The evaluation of tumor response after the first two cycles of chemoimmunotherapy was consistent with progressive disease with clinically relevant abdominal pain caused by larger involvement of peripancreatic lymph node metastasis. Given the poor performance status, the patient was offered best supportive care alone. Death occurred twelve months after the detection of the lung tumor.

Discussion

PEAC is a rare entity of NSCLC whose diagnosis implies the exclusion of a mCRC. The patient we presented had a low-grade pT1 CRC resected endoscopically five years prior to the appearance of



the pulmonary tumor. However, the possibility of mCRC to the lung was ruled out due to the absence of histologically confirmed local recurrence and the absence of other distant lesions.

For the diagnosis of PEAC it is recommended to use an immunohistochemical panel including pulmonary and enteric markers and that at least one of the enteric is positive among CDX2, CK20, HNF4a, or MUC2 and desirably with co-expression of TTF1 or CK7 [4]. Our case was positive for TTF-1, CK20, and CDX2. Although CK7 characterizes lung cells and is the most frequently expressed marker in PEAC [9,10,12-19], in our case it was negative like other reported cases [20,21]. In addition, other new markers such as cadherin-17, SATB2, and β -catenin have proven useful in the differential diagnosis between PEAC and mCRC [12,18]. In particular, SATB2 has been very effective in recognizing mCRC among lung adenocarcinomas [22]. We found that expression of the enteric marker CDX2 was observed in both glandular and NEC components, whereas SATB2 was expressed only in the epithelial component. This is consistent with current knowledge on SATB2 expression in neuroendocrine tumors: Intense SATB2 expression is observed in well-differentiated neuroendocrine tumors of the lower gastrointestinal tract but among NEC it is only strongly expressed in Merkel's carcinoma [23]. Recently, other methods such as DNA methylation profiling have been proven to be a powerful tool to distinguish PEAC from mCRC [14].

To the best of our knowledge, a NEC within a PEAC has not been previously described in the literature. Among other rare related cases reported we have found a rare case of CK7/CK20 negative PEAC with transformation to a conventional pulmonary carcinoma [24]. Considering that in CRC the presence of two cell lines, one glandular and the other NE, defines a MANEC, we have estimated the diagnosis of PEMANEC of the lung for the present neoplasm.

Currently, no specific recommendations for the treatment of PEAC exist, even less in the context of a NEC component as in our case. NGS can provide a better understanding of the molecular landscape of PEAC and serve as a guiding tool for treatment selection [16,18,20]. As PEAC is histologically regarded as a lung adenocarcinoma, treatment options apply as for non-squamous NSCLC. In the metastatic setting without an actionable oncogenic driver, first-line treatment with platinum-based doublet chemotherapy in combination with immunotherapy should be considered [25].

KRAS mutations are detected in 40% to 50% of PEACs, being the most frequent molecular alteration in these tumors, associated with tobacco use [26] and shorter survival [27]. Recently sotorasib has shown anticancer activity in patients with previously treated *KRAS* p.G12C-mutated NSCLC [28]. The fact that the tumor showed *CDK6* amplification in metastatic progression could open new therapeutic opportunities. *CDK4/6* inhibitor therapies have shown antitumor activity in hormone receptor-negative HER2-negative advanced metastatic breast cancer and are already approved by the FDA in this setting [29]. The role of cyclin inhibitors in patients with *CDK4/6*-amplified lung cancer remains an area of investigation.

Prognosis of PEAC is dismal and survival rates for stage IV disease treated with chemotherapy range from 2 to 12 months [1]. Our particular case followed an aggressive behavior with distant metastasis at 3 months and the patient's death occurred 12 months after the diagnosis of the lung tumor.

Conclusion

We report the first description of a PEMANEC applying the same criteria as in CRC, where the presence of two cell lines in a neoplasm, one glandular and the other neuroendocrine, defines a MANEC.

Acknowledgement

The authors thank clinical and laboratory staff from the Departments of Pathology and Medical Oncology at Hospital Universitari General de Catalunya-Grupo Quirónsalud and the Laboratory of Pangaea Oncology at Hospital Universitari Quirón Dexeus for technical support.

References

- Li H, Cao W. Pulmonary enteric adenocarcinoma: A literature review. *J Thorac Dis.* 2020;12(6):3217-26.
- Palmirotta R, Lovero D, D'Oronzo S, Todisco A, Internò V, Mele F, et al. Pulmonary enteric adenocarcinoma: An overview. *Expert Rev Mol Med.* 2020;22:e1.
- Tsao MS, Fraser RS. Primary pulmonary adenocarcinoma with enteric differentiation. *Cancer.* 1991;68(8):1754-7.
- Jain D, MacMahon H, Nakatani FA, Soares FA, Zhang J. Enteric-type adenocarcinoma of the lung. In: WHO Classification of Tumours. Thoracic Tumours. 5th Ed. Lyon, France: International Agency for Research on Cancer (IARC); 2021:83-4.
- Rindi G, Komminoth P, Scoazec JY, Shia J. Colorectal neuroendocrine neoplasm. In: WHO Classification of Tumours. 5th Ed. Digestive System Tumours. Lyon, France: International Agency for Research on Cancer (IARC); 2019:188-91.
- Morita S, Yoshida A, Goto A, Ota S, Tsuta K, Yokozawa K, et al. High-grade lung adenocarcinoma with fetal lung-like morphology: Clinicopathologic, immunohistochemical, and molecular analyses of 17 cases. *Am J Surg Pathol.* 2013;37(6):924-32.
- Suzuki M, Yazawa T, Ota S, Morimoto J, Yoshino I, Yamanaka S, et al. High-grade fetal adenocarcinoma of the lung is a tumour with a fetal phenotype that shows diverse differentiation, including high-grade neuroendocrine carcinoma: A clinicopathological, immunohistochemical and mutational study of 20 cases. *Histopathology.* 2015;67(6):806-16.
- Ricaurte LM, Arrieta O, Zatarain-Barrón ZL, Cardona AF. Comprehensive review of fetal adenocarcinoma of the lung. *Lung Cancer (Auckl).* 2018;9:57-63.
- Wang CX, Liu B, Wang YF, Zhang RS, Yu B, Lu ZF, et al. Pulmonary enteric adenocarcinoma: A study of the clinicopathologic and molecular status of nine cases. *Int J Clin Exp Pathol.* 2014;7(3):1266-74.
- Zhao L, Huang S, Liu J, Zhao J, Li Q, Wang HQ. Clinicopathological, radiographic, and oncogenic features of primary pulmonary enteric adenocarcinoma in comparison with invasive adenocarcinoma in resection specimens. *Medicine (Baltimore).* 2017;96(39):e8153.
- Nottegar A, Tabbò F, Luchini C, Guerrera F, Gaudiano M, Bria E, et al. Pulmonary adenocarcinoma with enteric differentiation: Dissecting oncogenic genes alterations with DNA sequencing and FISH analysis. *Exp Mol Pathol.* 2017;102(2):276-9.
- Bian T, Zhao J, Feng J, Zhang Q, Qian L, Liu J, et al. Combination of cadherin-17 and SATB homeobox 2 serves as potential optimal makers for the differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal adenocarcinoma. *Oncotarget.* 2017;8(38):63442-52.
- Nottegar A, Tabbò F, Luchini C, Brunelli M, Bria E, Veronese N, et al. Pulmonary adenocarcinoma with enteric differentiation: Immunohistochemistry and molecular morphology. *Appl Immunohistochem Mol Morphol.* 2018;26(6):383-7.

14. Jurmeister P, Schöler A, Arnold A, Klauschen F, Lenze D, Hummel M, et al. DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer. *Mod Pathol*. 2019;32(6):855-65.
15. Jurmeister P, Vollbrecht C, Behnke A, Frost N, Arnold A, Treue D, et al. Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options. *Lung Cancer*. 2019;138:43-51.
16. Zhang J, Xiang C, Han Y, Teng H, Li X, Shao J, et al. Differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma with the assistance of next-generation sequencing and immunohistochemistry. *J Cancer Res Clin Oncol*. 2019;145(1):269-79.
17. Chen M, Liu P, Yan F, Xu S, Jiang Q, Pan J, et al. Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: Implications for differential diagnosis and immunotherapy. *J Transl Med*. 2018;16(1):81.
18. Matsushima J, Yazawa T, Suzuki M, Takahashi Y, Ota S, Nakajima T, et al. Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: Usefulness of SATB2 and β -catenin immunostaining for differentiation from metastatic colorectal carcinoma. *Hum Pathol*. 2017;64:179-85.
19. Lin L, Zhuang W, Wang W, Xu C, Chen R, Guan Y, et al. Genetic mutations in lung enteric adenocarcinoma identified using next-generation sequencing. *Int J Clin Exp Pathol*. 2017;10(9):9583-90.
20. Li HC, Schmidt L, Greenson JK, Chang AC, Myers JL. Primary pulmonary adenocarcinoma with intestinal differentiation mimicking metastatic colorectal carcinoma: Case report and review of literature. *Am J Clin Pathol*. 2009;131(1):129-33.
21. Hatanaka K, Tsuta K, Watanabe K, Sugino K, Uekusa T. Primary pulmonary adenocarcinoma with enteric differentiation resembling metastatic colorectal carcinoma: A report of the second case negative for cytokeratin 7. *Pathol Res Pract*. 2011;207(3):188-91.
22. Kriegsmann M, Harms A, Longuespée R, Muley T, Winter H, Kriegsmann K, et al. Role of conventional immunomarkers, HNF4- α and SATB2, in the differential diagnosis of pulmonary and colorectal adenocarcinomas. *Histopathology*. 2018;(6):997-1006.
23. Bellizzi AM. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: What can brown do for you? *Hum Pathol*. 2020;96:8-33.
24. Miyaoka M, Hatanaka K, Iwazaki M, Nakamura N. CK7/CK20 double-negative pulmonary enteric adenocarcinoma with histopathological evaluation of transformation zone between enteric adenocarcinoma and conventional pulmonary adenocarcinoma. *Int J Surg Pathol*. 2018;26(5):464-8.
25. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. ESMO Guidelines Committee. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018;29(Suppl 4):iv192-237.
26. Slebos RJ, Hruban RH, Dalesio O, Mooi WJ, Offerhaus GJ, Rodenhuis S. Relationship between K-RAS oncogene activation and smoking in adenocarcinoma of the human lung. *J Natl Cancer Inst*. 1991;83(14):1024-7.
27. Mitsudomi T, Steinberg SM, Oie HK, Mulshine JL, Phelps R, Viallet J, et al. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. *Cancer Res*. 1991;51(18):4999-5002.
28. Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GA, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. *N Engl J Med*. 2021;384(25):2371-81.
29. Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. *Int J Mol Sci*. 2020;21(6):1960.